<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03136029</url>
  </required_header>
  <id_info>
    <org_study_id>F1311-R</org_study_id>
    <nct_id>NCT03136029</nct_id>
  </id_info>
  <brief_title>Exercise and NO in HFrEF</brief_title>
  <official_title>Overcoming Exercise Intolerance in Veterans With Heart Failure: The Role of NO.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart disease is the leading cause of death in the United States, accounting for one in every&#xD;
      four deaths in 2010 and costing over $300 billion annually in health care, medication, and&#xD;
      lost productivity. Heart failure with a reduced ejection fraction (HFrEF), a clinical&#xD;
      syndrome that develops as a consequence of heart disease, now affects almost 6 million&#xD;
      Americans. Within the VA Health Care System, HFrEF hospital admission rates continue to rise,&#xD;
      and remain the number one reason for discharge from VA hospitals nationwide. Unfortunately,&#xD;
      over one-third of all Veterans suffering from HFrEF die within two years of discharge despite&#xD;
      optimized drug therapy, an unacceptably high number. This proposal is focused on how impaired&#xD;
      muscle blood flow contributes to exercise intolerance in HFrEF, and on subsequently&#xD;
      developing strategies for restoring exercise tolerance and slowing disease progression in&#xD;
      this patient group. It is anticipated that knowledge gained from these studies will&#xD;
      contribute to improved standard of care, quality of life, and prognosis in this VA patient&#xD;
      group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure with reduced ejection fraction (HFrEF), a clinical syndrome that develops as a&#xD;
      consequence of heart disease from multiple etiologies, now affects almost six million&#xD;
      Americans, presenting an imminent need for further research addressing the pathophysiology of&#xD;
      this pervasive disease. One of the most damaging consequences of the disease is an elevation&#xD;
      in sympathetic nervous system (SNS) activity, which manifests peripherally as chronic&#xD;
      vasoconstriction. In HFrEF patients, peripheral vasoconstriction acts to limit blood flow in&#xD;
      the exercising muscle, promoting exercise intolerance, premature skeletal muscle fatigue,&#xD;
      inactivity, and a subsequent acceleration in disease progression. Fortunately,&#xD;
      disease-related sympathoexcitation may be remediable. Among the most influential modulators&#xD;
      of peripheral SNS expression is the nitric oxide (NO) pathway. Thus, interventions focused on&#xD;
      improving NO bioavailability may offer a new, unexplored strategy for inhibiting SNS&#xD;
      overactivity in HFrEF, and thus represent a novel approach for improving and exercise&#xD;
      tolerance.&#xD;
&#xD;
      Specific Aim 1 will utilize an oral antioxidant (AOx) cocktail to study whether disruptions&#xD;
      in oxidative stress can favorably influence exercise tolerance in HFrEF patients.&#xD;
&#xD;
      Specific Aim 2 will examine the efficacy of oral tetrahydrobiopterin (BH4), a cofactor for&#xD;
      endothelial nitric oxide synthase (eNOS), to improve exercise intolerance in HFrEF patients.&#xD;
&#xD;
      Specific Aim 3 will examine the therapeutic potential of aerobic, knee-extensor (KE) exercise&#xD;
      training to improve skeletal muscle blood flow and thus exercise tolerance in HF patients.&#xD;
      Importantly, this exercise modality produces a potent training stimulus without the&#xD;
      significant cardiopulmonary stress that accompanies more traditional, whole-body exercise. It&#xD;
      is proposed that 12 weeks of supervised KE training will increase NO bioavailability and&#xD;
      inhibit SNS activity, which will in turn improve vascular function and exercising limb blood&#xD;
      flow.&#xD;
&#xD;
      Specific Aim 4 will examine whether the interventional strategies in Aims 1-3 can improve&#xD;
      adherence to an 8-week clinical cardiac rehabilitation program. It is hypothesized that&#xD;
      chronic AOx consumption (Aim 1), BH4 consumption (Aim 2), and aerobic exercise training (Aim&#xD;
      3) interventions will reduce the rate of attrition from Phase II outpatient Cardiac&#xD;
      Rehabilitation in HFrEF patients compared to patients that did not participate in an&#xD;
      interventional phase of the study.&#xD;
&#xD;
      The investigators anticipate that disrupting this &quot;vicious cycle&quot; of vasoconstriction in&#xD;
      HFrEF may improve overall vascular health to such a degree that significant improvements in&#xD;
      exercise-related symptoms are realized, which could therefore improve enrollment in a cardiac&#xD;
      rehabilitation program. In this context, findings from the proposed work may provide an&#xD;
      important link between vascular and rehabilitative medicine, thus serving to refine current&#xD;
      strategies for the treatment of Veterans with HFrEF, ultimately leading to enhanced quality&#xD;
      of life in this cohort.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Flow</measure>
    <time_frame>four years</time_frame>
    <description>ultrasound Doppler</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Heart Failure With Reduced Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Oral AOx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 week oral antioxidant treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral AOx (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for arm 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral BH4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 week oral tetrahydrobiopterin treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral BH4 (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for arm 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ex training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8-week knee-extensor exercise training program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ex training (attn con)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Attention control for arm 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Antioxidant</intervention_name>
    <description>Daily consumption of over-the-counter vitamins (600mg alpha lipoic acid, 1000mg vitamin c, 600IU vitamin E)</description>
    <arm_group_label>Oral AOx</arm_group_label>
    <arm_group_label>Oral AOx (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Tetrahydrobiopterin (BH4)</intervention_name>
    <description>Daily consumption of BH4 (10mg/kg)</description>
    <arm_group_label>Oral BH4</arm_group_label>
    <arm_group_label>Oral BH4 (placebo)</arm_group_label>
    <other_name>Kuvan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise training</intervention_name>
    <description>Aerobic exercise training program (3x/week for 8 weeks, 1 hour per session)</description>
    <arm_group_label>Ex training</arm_group_label>
    <arm_group_label>Ex training (attn con)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General Inclusion/Exclusion Criteria:&#xD;
&#xD;
          -  The study group will include subjects with a history of stable cardiomyopathy&#xD;
             (ischemic and non-ischemic, &gt;3 months duration, ages 45-75 yrs) despite a minimum of 6&#xD;
             weeks of optimal treatment.&#xD;
&#xD;
          -  Optimal therapy will be according to American Heart Association (AHA) /American&#xD;
             College of Cardiology (ACC) and Heart Failure Society of America (HFSA) HF guidelines,&#xD;
             including treatment with angiotensin-converting enzyme (ACE) and -blocker therapy (for&#xD;
             at least 6 weeks), or have documented reason for variation, including medication&#xD;
             intolerance, contraindication, patient preference, or personal physician's judgment.&#xD;
&#xD;
          -  Patient enrollment will be limited to those individuals with New York Heart&#xD;
             Association (NYHA) class II and III symptoms, left ventricular ejection fraction &lt;35%&#xD;
             (LVEF), with no or minimal smoking history (&lt;15 pk yrs), and without pacemakers.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with atrial fibrillation or HF believed to be secondary to atrial&#xD;
             fibrillation will be excluded.&#xD;
&#xD;
          -  Patients with HF secondary to significant uncorrected primary valvular disease (except&#xD;
             mitral regurgitation secondary to left ventricular dysfunction) will also be excluded.&#xD;
&#xD;
          -  Patients will be sedentary, defined here as no regular physical activity for at least&#xD;
             the prior 6 months and current activity level will be documented by an activity&#xD;
             questionnaire.&#xD;
&#xD;
          -  Patients must have no orthopedic limitations that would prohibit them from performing&#xD;
             knee-extensor exercise.&#xD;
&#xD;
          -  Due to the typical age of patients with HF, all women will be postmenopausal (either&#xD;
             natural or surgical) defined as a cessation of menses for at least 2 years, and in&#xD;
             women without a uterus, follicle stimulating hormone (FSH) &gt;40 IU/L.&#xD;
&#xD;
          -  Women currently taking hormone replacement therapy (HRT) will be excluded from the&#xD;
             proposed studies due to the direct vascular effects of HRT Comorbidity Exclusion&#xD;
             Criteria: Patients with significant non-cardiac comorbidities, which if present could&#xD;
             alter the study results, will be excluded.&#xD;
&#xD;
               -  These include a diagnosis of Dementia&#xD;
&#xD;
               -  Severe chronic obstructive pulmonary disease (COPD)&#xD;
&#xD;
               -  Peripheral Vascular Disease&#xD;
&#xD;
               -  Anemia&#xD;
&#xD;
               -  Sleep-related Breathing Disorder&#xD;
&#xD;
               -  Severe Valvular Heart Disease&#xD;
&#xD;
               -  Diabetes (if on insulin therapy)&#xD;
&#xD;
               -  or End-stage Malignancy&#xD;
&#xD;
          -  The investigators will also exclude morbidly obese patients (BMI &gt;40), patients with&#xD;
             uncontrolled Hypertension (&gt;160/100), Anemia (Hgb&lt;9) and Severe Renal Insufficiency&#xD;
             (individuals with creatinine clearance &lt;30 by the Cockcroft-Gault formula).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David W. Wray, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Salt Lake City Health Care System, Salt Lake City, UT</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David W Wray, PhD</last_name>
    <phone>(801) 582-1565</phone>
    <phone_ext>4162</phone_ext>
    <email>walter.wray@hsc.utah.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Russell S Richardson, PhD</last_name>
    <phone>(801) 582-1565</phone>
    <phone_ext>4344</phone_ext>
    <email>r.richardson@hsc.utah.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VA Salt Lake City Health Care System, Salt Lake City, UT</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David W Wray, PhD</last_name>
      <phone>801-582-1565</phone>
      <phone_ext>4162</phone_ext>
      <email>walter.wray@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Douglas S Capps, BS</last_name>
      <phone>(801) 582-1565</phone>
      <phone_ext>4414</phone_ext>
      <email>scott.capps@hsc.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David W. Wray, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 27, 2017</study_first_submitted>
  <study_first_submitted_qc>April 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2017</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HFrEF</keyword>
  <keyword>Exercise Intolerance</keyword>
  <keyword>Nitric Oxide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

